News & Events RSS Feed

13 December 2017


The Company held its Annual General Meeting at its offices in Oxford on 13th December 2017 Click here to read more

12 December 2017

Director Dealing

The Company announces that it received notice today that the following Directors sold the following number of ordinary shares in the Company at the following prices per share: Click here to read more.

6 December 2017

Issue of Equity

Physiomics plc announces today that following the receipt of notice of exercise of employee options, 1,768,815 Ordinary Shares of 0.4p each in the Company (the “Options Shares”) have now been issued to the following employees at the following exercise prices: Please click here to read more.

30 November 2017

Share Price Movement

Following the movement in the Physiomics share price today the Company would like to draw investors’ attention to its RNS of the 28th of November in which the Company announced the signing of a Master Services Agreement (“Agreement”) with Merck KGaA whose minimum value in the first twelve months of the contract is €500,000 (equivalent […]

28 November 2017

Completion of VT Clinical Project with Merck and announcement of Master Services Agreement

Physiomics plc (AIM: PYC) is pleased to announce that the human Virtual Tumour (“VT”) project with Merck, a leading science and technology company, first announced in March 2015, has now been successfully completed and that it has today entered into a Master Services Agreement (“Agreement”) with Merck. Please click here to read in full

9 November 2017

Dispatch of Annual Report and Shareholder Circular

  Dispatch of Documentation Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has published and posted to shareholders its Annual Report for the financial year ended 30th June 2017 and a circular in relation to its forthcoming Annual General Meeting As already announced on the 16th […]

16 October 2017

Final Results for the year ended 30 June 2017

  Chairman's Statement Summary of Results in the year ended 30 June 2017 Total income (revenue and grant income) decreased 9% to £270,465 (2016: £297,120) The operating loss before exceptional costs increased 20% to £489,190 (2016: £408,614) The loss for the year attributable to equity shareholders increased 6% to £400,526 (2016: £378,697) On 30 June […]

Page 1 of 2312345...1020...Last